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1. Introduction 
 
Neuroblastoma is the most commonextracranial solid tumor occurring in infancy and the 
second most commonly occurring in children. It is the neoplasm of the sympathetic nervous 
system. (Park et al., 2008). Neuroblastoma is characterized by the complex framework of 
genetic irregularities interrelated to determine the clinical phenotype. Neuroblastoma is 
distinguished by somatically gained genetic events that conduct a result of gene overexpression 
(oncogenes), gene inactivation (tumor suppressor gene), or modifications in gene expression. 
N-Myc proto-oncogene is known to be amplified in 20% to 25% of neuroblastomas, which 
plays multiple roles in malignancy and of maintenance of stemness (Maris & Matthay, 1999). 
In neuroblastoma, the important tumor suppressor gene TP53 is wild type in most of the patients 
at diagnosis, through overexpression of its negative regulators (Mdm2 or MDMX) and other 
unknown mechanisms (Tweddle et al., 2003). The p53 has shown to down-regulate N-Myc at 
protein level in neuroblastoma (Burmakin et al., 2013).  
 
Therefore, it was tempting to study the combinatorial effects of N-Myc inhibition and p53-
activation for complete tumor regression in neuroblastoma, as the high-risk neuroblastoma with 
N-Myc amplification frequently leads to a fatal clinical outcome even though multimodal 
therapy, there is a need to develop more targeted strategies by targeting both oncogene (N-Myc) 
and tumor suppressor (p53). The combination of two anti-cancer treatments can increase 
efficiency due to targeting different pathways or by acting in a synergetic or additional manner 
(Mokhtari et al., 2017). 
 
A number of studies have succeeded to find molecules that appear to restore proper tumor 
suppressor activity of p53 both in vitro and in vivo (Sanz et al., 2019). Moreover, finding the 
small molecules to target N-Myc is quite challenging. Recently, small molecules MI-6, which 
inhibit MYC-MAX (heterodimer important for MYC-driven transcription activation) showed 
promising in vitro response (Castell, Yan, Fawkner, Hydbring, et al., 2018a). Notably, several 
studies indicate that the N-Myc amplification in neuroblastoma is associated with repressed 
cellular immunity (P. Zhang et al., 2017). MYC oncogene represses immune surveillance both 
directly and indirectly in different cancers (Casey et al., 2017, 2018). Several studies suggest 
that p53 can influence innate immune responses as part of its tumor suppressor activities (Sanz 
et al., 2019) but the detailed mechanism is still under investigation. 
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It has been suggested that p53 and Myc inverse regulate several common target genes 
expression including innate immune genes. In this study, we tried to get a better understanding 
of the innate immune response by inhibition of N-Myc using MYCMI-6 and activation of p53 
using ATSP-7041 and Nutlin-3. Interestingly, monitoring p53 and MYC level, tumor cell 
expression of endogenous retroviral elements (ERVs) increased which leads to enhanced 
STAT1 expression, activity and followed by HLA class I expression has been significantly 
enriched. Our findings suggest that MYC inhibitor and p53 activators increase tumor 
immunogenicity and provide a rationale for new combination regimens comprising N-Myc 
inhibitor and p53-activators as an anti-cancer treatment.  
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2. Review of literature 
 
2.1. Cancer 
 
Cancer, which is defined as indigenous cells, abnormal cells that arise from one’s own 
normal tissues not from cells that were introduced into the body by infection from another 
person. It is a disease that originates when a single normal body cell undergoes complex 
and successive genetic and epigenetic aberrations that transforms onto a cancer cell. 
Through years of proliferation, and uncontrolled growth, this cell and its successors become 
a population of cells which is recognized as a tumor. Consequently, this tumor builds-up 
the symptoms of what is known as cancer. Although a tumor is monoclonal in origin; 
meaning that it was originally acquired from a single ancestral cell, but tumor is like an 
organ which consists of varying characterized cells including non-cancerous cells as 
fibroblasts, vascular endothelial cells, pericytes, extracellular matrix and innate and 
adaptive immune cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Tumor microenvironment (Cui & Guo, 2016). This figure shows the tumor immunological 
construction of the tumor microenvironment. It is made up of cellular components and molecular 
components. The cellular components are comprised of immune cells derived from hematopoietic 
origin and stromal cells derived from non-hematopoietic origin. The immune cells include tumor-
infiltrating T, B, and natural killer cells. It also includes myeloid populations of macrophages, 
myeloid-derived suppressor cells, and dendritic cells. The stromal cells are comprised of cancer-
associated fibroblasts and endothelial cells. 
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2.2. Hallmarks of cancer 
 
During the successive multi-step process of genetic and epigenetic aberrations that the 
precancerous cell undergoes, it attains the features that generate the malignant growth of 
cancer cells, features which enable the cancer cell to survive, grow, proliferate and disperse. 
Almost every cancer type, if not all, acquire those set of traits that is defined as the hallmarks 
of cancer. These six include the ability to sustain proliferative signaling, the ability to evade 
growth suppressors, acquired resistance to cell death, induction of angiogenesis, activation 
of tissue invasion and metastasis, and uncontrolled unstoppable replication (Hanahan & 
Weinberg, 2011). 
 
 
 
These six fundamental hallmarks of cancer have been updated with additional two which are 
believed to play role in the pathogenesis of again some and might be all types of cancer. These 
two include formatting cellular energetics; consequently, results in genome instability and 
mutation. The second one is the ability to evade immune surveillance by T and B lymphocytes, 
macrophages, and natural killer cells; thus, leading to tumor-promoting inflammation (Hanahan 
& Weinberg, 2011). 
Figure 2: The six hallmarks of cancer and the acquired traits of cancer (Hanahan & 
 Weinberg, 2011)  
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2.2.1. Sustaining proliferative signaling 
 
One of the most prominent features of a cancer cell is that it can proliferate continuously and 
independently, without external stimuli. In a normal cell, there is a tight regulation of both the 
growth-encouraging and growth-inhibiting factors by mitogenic growth signals, to assure 
normal cell number, tissue construction and function. However, in cancer cells, this cascade of 
tight control is disrupted and cells proliferate in despite of proliferative signaling; hence, 
uncontrollable and unstoppable growth.  
In neuroblastoma, the growth is governed by multiple growth factors which communicate with 
specific receptor tyrosine kinases and non-receptor tyrosine kinases available at cancer cell. 
Some of these include the neurotrophin receptors, TrkA/NTRK1, TrkB/NTRK2 and 
TrkC/NTRK3, where they attach to a family of cognate ligands such as nerve growth factor 
(NGF), brain-derived neurotropic factor (BDNF) and neurotrophin-3 (NT3), respectively 
(Brodeur et al., 2009). These receptors have various roles on growth and development, TrkA 
and TrkB have contrast roles for example, where the former curb proliferation when in contrast 
TrkB encourages proliferation and development. These receptors have a couple of mechanisms 
that could lead to its activation, as previously mentioned through autocrine or paracrine 
Figure 3: Two additional hallmarks of cancer unfolded (Hanahan & Weinberg, 2011) 
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activation (Brodeur et al., 2009). It has been reported that numerous neuroblastoma tumors that 
on-the-spot develop such as ganglioneuroblastoma are well-supplied in Schwann cells, which 
in turn are bountiful root of NGF and other neutrotrophins that result in immature N-Myc-
amplified and non-amplified neuroblastoma cell lines (Ambros et al., 1996; Kwiatkowski et al., 
1998). One more thing that conduce a shoddy clinical outcome in neuroblastoma is credited to 
the cytokine receptor interleukin-6 (IL-6). It is often found vastly expressed in high-risk N-Myc 
non-amplified human cancers; whereas, the proteins gp130 and gp80 that construct this 
receptor, are expressed in the majority of human neuroblastoma cell lines, in both the N-Myc- 
amplified and non-amplified (Ara et al., 2013).  
 
2.2.2. Evading growth suppressors 
 
Cancer cells couple the sustained proliferative signaling and the constitutive stimulation of 
growth-stimulatory signals, together with evasion of growth suppressors and signals to 
negatively regulate cell proliferation. This outcome is mostly gained by the action of the tumor 
suppressor genes. Tumor suppressor genes function differently to restrict cell growth and 
proliferation. The two most important genes are the retinoblastoma-associated (Rb) and tumor 
protein 53 (Tp53). They behave as central control nodes which pilot two of the most 
fundamental cellular regulatory circuits, activation of senescence or growth arrest and apoptotic 
programs. These genes are frequently mutated or inactivated in all human cancers.  
The Rb protein obtains signals extracellularly and intracellularly originated which dictates 
whether a cell should run through growth-and-division cycle. On the other side, p53 collects 
inputs from stress, abnormalities and disrupted cell cycle continuation and for as long as the 
system is not functioning normally yet.  
In neuroblastoma, p53 is the main tumor suppressor, however, it is often found wild-type at 
diagnosis or even at recurrence (Tweddle et al., 2003). Therefore, it is suggested that the 
variance in MDM2 pathway might be the medium that gives carte blanche to evade growth 
suppressors (T. Van Maerken et al., 2009).  
 
2.2.3. Enabling replicative immortality 
 
Under normal conditions, healthy cells are only restricted to undergo certain number of cell 
division cycles where after they face senescence, this phenomenon is known as “Hayflick 
limit”; in contrast, the tumor cells where they exhibit unrestricted replication to form tumors. 
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Telomeres, the chromosomes’ ends, play key role in restriction of this division, they are 
multiple repeats of the hexanucleotide “TTAGGG” which preserves the ends of chromosomes 
from end-to-end fusions (Shay & Wright, 2000).  
In neuroblastoma tumors, telomerase enzyme is surpassingly elevated as in most cancers, such 
elevation is correlated with N-Myc amplification and the unsatisfactory clinical outcome 
(Hiyama et al., 1995). Recent studies have showed that telomerase activity in neuroblastoma is 
under regulation by the tumor microenvironment especially by the inflammatory monocytes 
and macrophages. It has also been proven that the relocation of the microRNA-21 via exosomes 
from the neuroblastoma cells to these inflammatory monocytes caused dispense of microRNA-
155. These microRNA-155 intend the telomeric repeat-binding factor 1 (TERF1) directly in the 
neuroblastoma cells. TERF1 is an inhibitor of telomerase; hence, telomerase activity is elevated 
(Challagundla et al., 2015).  
 
2.2.4. Activating invasion and metastasis 
 
In the tumor site, cells experience morphological changes which affect their cell-cell or cell-
matrix interplay and in turn aid them successfully get through the first steps of the multistep 
process of invasion and metastasis. It is a stream of biological changes that permit cancer cells 
to migrate from its original starting place to new healthy tissues, ensuing intravasation into 
blood and lymphatic vessels (Fidler, 2003). 
In neuroblastoma, the sites for metastasis are the bone marrow, liver and bones in patients with 
stage IV neuroblastoma (DuBois et al., 1999).  Majority of the cell lines acquired from high-
risk patients exhibited receptors CXCR4 and CXCR7 which are the receptors for CXCL12 
chemokine, or to which is also known as stromal-derived factor-1 (SDF-1). The former receptor 
is commonly correlated with the more combative undifferentiated tumors; however, the latter 
receptor CXCR7 often linked and expressed in more differentiated and mature tumors. 
Metastasis to the liver and lungs is shined out to when the CXCR4 is overly expressed in 
neuroblastoma, while when it is the CXCR7 that is overly expressed the adrenal gland and the 
liver are more favored. In case, they are both simultaneously expressed, neuroblastoma 
dissemination is greatly directed to face the bone marrow (Geminder et al., 2001; Liberman et 
al., 2012; Russell et al., 2004).  
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2.2.5. Inducing angiogenesis 
 
Logically, when cancer cells multiply and proliferate, tumor mass and size increases. In 
consequence, natural and normal diffusion of oxygen and nutrients could be restricted, which 
are needed for further growth of the tumor. Herein, the need of this hallmark capability; 
induction of angiogenesis. This process is defined as the formation of new blood vessels from 
existing vasculature, which maintains constant delivery of nutrients and oxygen to tumor site 
coupled with disposal of tumor’s metabolic wastes and facilitating of hematogenous metastatic 
process.  
In neuroblastoma, angiogenesis and vasculogenesis are induced as in most cancers. However, 
in neuroblastoma, MYCN induces the level of VEGF (Kang et al., 2008); even though tumor 
cells are mostly the roots for VEGF, neuroblastoma cells can trigger the production of VEGF 
through the bone marrow-derived mesenchymal stromal cells (MSC) which encourages the 
production of osteoblasts via an intracrine pathway (Haduong et al., 2015).  
 
2.2.6. Resisting cell death 
 
It is well established by many studies that programmed cell death, or apoptosis serves as a 
barricade against tumor advancement. It is normally activated by certain physiological stresses, 
both by internal and external stimuli that cancer cells endure thorough the process of 
tumorigenesis. These include signaling imbalance, unrestrained proliferation, and irreversible 
DNA damage. However, highly malignant cancers can diminish this programmed cell death, 
and even become resistant to therapy. (Lowe et al., 2004).  
When DNA damage occurs via chemotherapeutic agents, apoptosis is initiated through the 
tumor protein 53 (p53), consequently downstream genes are triggered leading to cell death. 
Unfortunately, 50% of all human cancers have mutations in the p53 gene (Ferrara, 2009). 
Mutation of this protein hinders cancer cells more resistant against cellular stresses that would 
trigger cell death.  
In neuroblastoma, defiance of caspase-8 expression through gene silencing or deletion is a 
prevailing twist contributes to the neuroblastoma’s aggressiveness and metastasis. This 
defiance eventuates the overlooking of the programmed cell death cancer feature. Not only that 
but, caspase-8 can irreconcilably assist migration and metastasis in neuroblastoma cell lines in 
way where it is not relying on its degrading or its apoptotic exertion; but relying on the contact 
with the extracellular matrix (ECM). A complex that is formed between caspase 8, FAK, 
 
 
9 
calpain2/CPN2 and calpastatin consequent to integrin ligation to ECM proteins interrupts the 
CPN2/calpastatin binding. Therefore, CPN2 is now activated and strengthening the breakage 
of focal adhesion substrates, resulting in MYCN amplified and non-amplified human 
neuroblastoma cell lines to migrate in vitro. (Barbero et al., 2009). Another mechanism that has 
a hand in resisting cell death is upregulation of anti-apoptotic proteins which aid cell survival 
in neuroblastoma, this upregulation is credited to the tumor microenvironment. For instance, 
IL-6 triggers STAT3 encourages the exhibition of various pro-survival proteins such as 
surviving, MCL-1 and Bcl-XL. (Ara et al., 2013). 
 
2.2.7. Reprogramming energy metabolism  
 
As previously mentioned, cancer cells possess the capability of sustained proliferation, this 
capability must be complemented with a supply of energy metabolism to fuel this constant 
proliferation, cell growth and division, and survival in harsh conditions. Normally, cells process 
glucose aerobically through glycolysis to pyruvate in the cytosol, then finally to carbon dioxide 
in the mitochondria in what is called Krebs cycle. However, in the absence of free oxygen, that 
is anaerobically, glycolysis is advantaged with almost no pyruvate relocated to the oxygen-
consuming mitochondria. In cancer cells, it has been observed by Otto Warburg that although 
presence of oxygen, glycolysis is still privileged, that is defined as “aerobic glycolysis”. This 
phenomenon is largely known as the “Warburg effect” (Hanahan & Weinberg, 2011).  
On the grounds that this metabolic switch takes place in cancer cells, there is approximately 18-
fold lower efficiency of ATP production supplied by glycolysis in comparison to the 
conventional mitochondrial oxidative phosphorylation that produces up to 36 ATP for each 
glycose molecule catabolized. So how can cancer cells counterpoise this deficiency? 
Upregulation of glucose transporters is one side of the key. Glut1, 2, 3, and 4 are notably 
upregulated, hence, more glucose uptake. Another way for making up the deficiency is by 
upregulating the expression of glycolytic enzymes, example of those oncogenes, which are 
upregulated and manifest extensive induction of cancer, are Ras, Myc, and HIF-1. Two of 
those oncogenes, c-Myc and HIF-1, and under lost or weakened control by p53, other 
glycolytic enzymes are transactivated directly or indirectly favoring glycolysis. The consensus 
Myc and HIF-1 binding motifs are abundantly found at the glycolytic gene promoter areas. It 
has been observed that HIF-1 is majorly working in hypoxia, whereas; c-Myc triggers the 
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expression of glycolytic genes under normoxia, advantaging the tumor with unceasing 
glycolysis, consequently; unstoppable proliferation and growth (Phan et al., 2014). 
In opposition to that, glucose uptake is abolished directly by inhibition of the transcription of 
the glucose transporters Glut1 and Glut3 by p53. Furthermore, p53 represses the activation of 
NF-B, accordingly; Glut3, which is a target gene of  NF-B is downregulated substantially. 
(Kawauchi et al., 2008). p53 induced glycolysis regulatory phosphatase (TIGAR) is also 
another gene its expression is affected positively by p53, to serve as a brake to the cancer 
glycolysis. TIGAR reconverts fructose 2,6-bisphosphanate which is an allosteric activator of a 
dominant glycolytic enzyme, PFK1, to fructose 1-phosphate (Bensaad et al., 2006; Bensaad & 
Vousden, 2007). Concluding the major role of TIGAR hindering the cancer glycolytic flux.  
 
However, p53 is almost always found mutated or malfunctioning in most human cancers.  
The possible justifications of why cancer cells favor this glycolytic switch is that more pyruvate 
is converted to lactate than usual which is a favored pathway as a result of the upregulation of 
lactate dehydrogenase A (LDHA) (DeBerardinis et al., 2008).  Cancer cells favor this pathway 
due to its generated NADH which serves as an accelerator to the glycolysis. Lactate also has 
another roe when it is secreted in the tumor microenvironment facilitated by the MCT4 
transporter, it feeds other cancer cells, those with shortage of constant nutrient supplies from 
blood stream. This synergy between both the lactate-producing and the lactate-utilizing tumor 
cells comes to fruition in terms of the tumor’s adaptation to the ongoing changing, chaos and 
diversity in the tumor microenvironment due to the leaky and scant tumor vasculature (Draoui 
& Feron, 2011; Semenza, 2008).  
Another advantage of this major shunting of pyruvate to lactate is that, less reactive oxygen 
species are produced, thereupon; tumor survival is enhanced as the level of oxidative stress in 
the tumor cells is lowered (Heiden et al., 2009; Yeung et al., 2008). Lactate can also switch the 
pH of extracellular microenvironment to a more acidic one, expediting cancer invasion and 
metastasis through easing the activity of metalloproteases for destructing extracellular matrix 
(Bonuccelli et al., 2010; Martinez-Outschoorn et al., 2011). 
Another hypothesis of why cancer cells favor this glycolytic switch is that the intermediates of 
this pathway get involved metabolically into various biosynthetic pathways such as generation 
of nucleosides and amino acids, thereby; enhanced synthesis of macromolecules and organelles 
required for constructing new cells. Aside from this metabolic function, glycolytic 
intermediates exhibit key roles in encouraging cancer survival, metastasis, invasion, chromatin 
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remodeling, gene expression regulation and many other crucial cellular processes (J. W. Kim 
& Dang, 2005; Yeung et al., 2008). 
In neuroblastoma, there is growing evidence that the Warburgian bias is not a result of a 
decreasing number of mitochondria. Upon detailed examination, equal levels of mitochondria 
in human NB samples in comparison to normal kidney tissue were detected (Lyser, 1974). 
Peculiarly, remarkable decrease in the copy numbers of mtDNA (mitochondrial DNA) was 
observed, along with inclusive reduced enzyme activity of OXPHOS (Oxidative 
phosphorylation) in NB samples (Feichtinger et al., 2010).  
One of the common chromosomal aberrations seen in advanced-stage NBs is the gain of 
chromosome 17. This gain results in overexpression of an anti-apoptotic protein 
BIRC5/Survivin. This protein is known to be enmeshed in this hall mark; reprogramming 
metabolism in NB. This protein tend to trigger fragmentation of mitochondria and lower 
mitochondria respiration (Hagenbuchner et al., 2013; Plantaz et al., 1997).  
Furthermore, N-Myc; which is amplified notably in half of all high-risk NBs, tend to correlate 
with the modulation of energy metabolism, either directly or indirectly through governing genes 
that take role in glycolysis, glutamine metabolism, fatty acids metabolism and mitochondrial 
function (Ren et al., 2015). This amplification of N-Myc seems to encourage the Warburg effect 
in NBs, by setting in motion the transcription of a few glycolytic genes (Qing et al., 2010).  
 
2.2.8. Evading immune destruction  
 
The healthy body has an immutable immune surveillance property which its key role is to 
suppress and abolish formation and advancement of emerging and late-stage tumors, and 
micrometastases. This means that the cells and tissues are under round-the-clock tight 
inspection against any formation or upraise of any changes leading to incipient neoplasia due 
to a failed intrinsic tumor suppressor mechanism. Therefore, this proves that cancer cells 
possess a capability that makes them evade immune surveillance, in other words; the concept 
of tumor immunoediting. In alignment with that, higher frequency of certain cancers is seen in 
immunocompromised human beings or at least more rapid growth of the tumor (Vajdic & Van 
Leeuwen, 2009). Nevertheless, most of these rising cancers are virally induced, this may give 
an insight about how decreasing the viral burden might negatively impact formation of these 
tumors. These findings brought us to the conclusion that, immune surveillance has the capacity 
to curb development of more than 80% of tumors of nonviral etiology. Immunodeficient mice 
were constructed to study the frequency of tumor formation and/or rapidness of growth 
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compared to immunocompetent. It has been shown specifically that loss of function or under 
developed CD8+ cytotoxic T lymphocytes (CTLs), CD4+ Th1 helper T cells (Th), or natural 
killer (NK) cells, any of these deficiencies manifested escalated tumor occurrence, with even 
higher prevalence or more aggressive development, if T cells and NK cells deficiencies were 
combined (Teng et al., 2008). In general, CTLs and Th cells produce interferons (IFN)- and 
cytotoxins to obstruct cancer development, however; some factors as chronic inflammation can 
counterbalance this obstruction and ease promotion of cancer (Zamarron & Chen, 2011).  
 
Immunoediting: the concept that explains why cancer can sometimes lie dormant in patients for 
years before re-emanating or why tumors can bypass or evade a fully functional immune system 
and proliferate (Dunn et al., 2002). Normally, immune system has the capacity to eradicate 
vulnerable cancer cells as they present tumor antigens, nevertheless; if genetic instability exists, 
it aids tumor cells to escape this immune surveillance by continuous tumor proliferation with 
reduced immunoreactivity. Cancer cells keep on dividing and accumulating mutational changes 
either through immune-induced inflammation or by chance, and this is counterbalanced by 
immune eradication, this equilibrium keep the tumor dormant. Nonetheless, eventually tumors 
gain the ability to halt the eradication by the immune system, by gaining immune suppressive 
effects or by overlooking the expression of target antigen, this is when the tumor starts to be 
clinically presented. Furthermore, some immune suppressed patients receiving organ 
transplants have demonstrated donor-derived cancers, supporting the concept of dormant 
cancers; whereas, the donor was tumor-free and the cancer cells were silenced in a dormant 
state, but when transplanted to an immune suppressed patient, cancer cells were triggered 
(Strauss & Thomas, 2010).  
In addition, highly immunogenic cancer cells can escape immune elimination through silencing 
elements of the immune system that is originally produced or excreted to eradicate them. Cancer 
cells tend to debilitate CTLs and NK cells by the action of immunosuppressive factors like 
TGF- (Lanza et al., 2019; Yang & Weinberg, 2008). Another defense mechanism that cancer 
cells can execute is employing inflammatory cells which are steadily immunosuppressive, such 
as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), where both can 
offset the action of CTLs (Mougiakakos et al., 2010; Ostrand-Rosenberg & Sinha, 2009). 
Additionally to what’s mentioned above, neuroblastoma cell lines normally have depressed 
levels of peptide presenting HLA class I molecules, meaning that recognition by CTLs is 
tarnished (Main et al., 1985). Once again, one of numerous roles of the tumor 
microenvironment is governing the expression of major histocompatibility complex (MHC) I 
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in neuroblastoma cell lines. The interferons generated by NK cells and T cells intensify the 
expression of MHC-I (Handgretinger et al., 1989; Lampson & Fisher, 1984). Also, 
NTRK1/TrkA when stimulated through bounding to NGF results in a heightened 
immunogenicity by overexpression of MHC-I (Pajtler et al., 2013); however, MYCN 
amplification, which is common in neuroblastoma,  elicit repression of MHC-I (Bernards et al., 
1986a). Previous studies have demonstrated evidence that, MYCN encompass paracrine 
regulative capacity on the immune cells found in the tumor microenvironment, N-Myc 
represses CCL2/MCP-1 (macrophage chemoattractant protein) which magnetize NKT cells in 
tumors (Metelitsa et al., 2004; Song et al., 2007a). 
 
Cancer cells also tend to induce a pro-tumorigenic inflammation. An inflammatory 
environment is initiated and mediated through the innate immune cells such as macrophages, 
monocytes and neutrophils found in the neuroblastoma cells, resulting in further tumor 
development and metastasis. It has been previously proven that neuroblastoma cells brainwash 
TAM to face a T-helper 2 mediated phenotype which reinforce tumor progression and 
development. Hence, when macrophage is detected in neuroblastoma tumors, it is correlated to 
an inferior outcome (Asgharzadeh et al., 2012; Larsson et al., 2015). 
 
2.3. Proto-oncogenes and tumor suppressor genes  
 
Two classes of genes have key role in either triggering or opposing cancer. These two are proto-
oncogenes and tumor suppressor genes. In a normal healthy cell, these two classes of genes 
together synchronize normal growth, which assures each tissue and organ is within the normal 
dimensions and structure for a healthy functioning body. When a mutation occurs, proto-
oncogenes are transformed to oncogenes, which triggers and encourages uncontrolled and 
immoderate growth. In alignment, when tumor-suppressor genes are mutated, their control of 
this immoderate division is disrupted, both of these mutations lead to overall increased growth 
and cell proliferation resulting in cancer (Understanding Cancer - NIH Curriculum Supplement 
Series - NCBI Bookshelf, n.d.).  
 
2.3.1. Proto-oncogenes and oncogenes 
 
Mutations that occur in proto-oncogenes are often dominant in nature meaning that only one of 
the two alleles if sufficient for induction of cancer, which is when mutated is defined as an 
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oncogene. Proto-oncogenes typically encode proteins with prominent impact on cells such as 
activation of cell division, cell differentiation repression, and constraining apoptosis. This 
impact is critical for normal human development and for the homeostasis of tissues and organs, 
and typically turned-off once the developmental process under regulation is attained. When 
proto-oncogenes are mutated and become oncogenes, those proteins with such powerful impact 
on the development are produced in abundance; bringing forth marked increase in cell 
proliferation, declined cell differentiation together with halting cell apoptosis, hence; they are 
not turned off and cancers may eventuate (Proto-oncogenes to Oncogenes to Cancer | Learn 
Science at Scitable, n.d.). In view of their phenotypes which define cancer, they are oftentimes 
found mutated or immensely overexpressed in tumor cells.  
The alteration or the changeover of a proto-oncogene into an oncogene can be attained through 
at least three processes, in general it includes a gain-of-function mutation. First mechanism is 
through point mutation in a proto-oncogene, subsequently; constitutive activation of the protein 
encoded. This mechanism yields an oncogene that on a small scale different from the encoded 
corresponding proto-oncogene. Secondly, overexpression of the protein product through gene 
amplification, or local reduplication of a certain DNA segment that carries the corresponding 
proto-oncogene. Thirdly, when a chromosome of a proto-oncogene gets translocated to a 
different chromosomal site and falls under the regulation of a new promoter with higher 
activity, causing, higher expression or the production of a fusion protein with oncogenic 
activity. The latter two mechanisms produce oncogenes typical to their proto-oncogenes, 
however; their oncogenic effect is a result of extremely elevated than normal expression level, 
or due to being expressed in cells, where under normal conditions not expressed there (Proto-
Oncogenes and Tumor-Suppressor Genes - Molecular Cell Biology - NCBI Bookshelf, n.d.). 
 
2.3.1.1. The MYC family 
 
One example of the protooncogenes are the MYC cellular oncogene family, which is made up 
of 3 well-defined genes, MYCL which encodes L-Myc, N-Myc which encodes N-Myc, and c-
MYC which encodes c-Myc or Myc. The role of L-Myc is not fully discovered; however, N-
Myc is expressed only in neuronal tissues and is restricted to certain stages of embryogenesis, 
pre B-cell development, kidney, forebrain, hindbrain and intestine, and it is able to displace 
Myc in murine development (Malynn et al., 2000).  
 
 
 
15 
MYC was first discovered through the studying of fulminant chicken tumors due to oncogenic 
retroviruses. It was discovered as a viral oncogene (v-MYC) that provokes myelocytomatosis 
(leukemia and sarcoma).(Duesberg & Vogt, 1979; Sheiness & Bishop, 1979). Its cellular 
homologue was later identified and obtained from chicken DNA (Vennstrom et al., 1982). 
According to further research, MYC is persistently remodeled by balanced chromosomal 
translocation in Burkitt lymphoma, which defined MYC as a bona fide human oncogene.(Dalla-
Favera et al., 1982; Taub et al., 1982). MYC is also constantly translocated in multiple 
myeloma, and found to be markedly amplified in different human cancers, making MYC 
alterations a constant key finding on the road to cancer (Beroukhim et al., 2010; Shou et al., 
2000). 
Myc has a critical role in tumorigenesis, cell proliferation and development. It has been found 
always highly elevated in dividing cells during development as well as in adult tissues. In other 
words, it is consistently expressed thorough the cell cycle of a proliferating cell, and represses 
to a minimum during quiescence (Depinho et al., 1987) 
Two of the Myc polypeptides created by the MYC mRNA are; one that commences at a CUG 
upstream of the canonical start codon AUG, and the second one commences at an internal AUG 
(Blackwood et al., 1994). The canonical AUG translates Myc protein with three domains: a N-
terminal transcriptional regulatory domain, a nuclear localization domain and a C-terminal 
DNA binding domain includes a basic helix-loop-helix-leucine zipper (bHLH-LZ) dimerization 
motif. Myc and MAX form a dimer to bind to the DNA sequence 5’-CACGTG-3’or alike 
sequence defined as E-boxes or enhancer boxes. Consequently, transcription activation takes 
place, and this is when Myc features numerous of its functions.  Myc binding to Max is crucial 
for Myc transforming scheme, as Myc homodimers are idle. This complex formed between 
Myc and Max appears to displace activators and recruit repressors, hence; repression of some 
genes (Amati et al., 1993; Blackwood & Eisenman, 1991; Eilers & Eisenman, 2008; Kretzner 
et al., 1992). The Myc polypeptide commencing at the upstream CUG has an unknown role, 
while, the shorter one commencing from an internal AUG seems to exhibit a role in stress 
response and might serve as a dominant negative Myc protein (Hann et al., 1992; Spotts et al., 
1997).  
Furthermore, Myc also seems to employ DNA replication licensing factors to catalyze DNA 
replication and it has been studied that Myc regulates the expression of up to collectively 15% 
of all genes. However, it is still unknown whether its transcriptional activity at replication 
origins is part-and parcel of its DNA replication function (Dominguez-Sola et al., 2007). 
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How MYC proto-oncogene is regulated? It is tightly regulated on both the transcriptional and 
the translational levels in non-transformed cells. MYC is regulated by a range of downstream 
transcription factors of the Wnt pathway such as CNBP, FBP and TCF. Also, it is governed by 
non-B DNA structures. Abnormalities in the expression of Myc is often due to deregulated 
upstream 
signaling, or due to amplification or translocation of the MYC gene (Boxer & Dang, 2001; 
Levens, 2010). The Myc protein has a half-life of about 15-20 minutes, which is a noticeably 
short half-life. Its transcriptional activity is synchronized by phosphorylation at Ser-62 followed 
by Thr-58, lastly followed by proteasomal degradation after carrying-out its function (Salghetti 
et al., 1999). Mutations at the Myc residues Thr-58 and Ser-62 could promote tumorigenesis 
through stabilizing of the mutant proteins and sustaining its level (Salghetti et al., 1999; Thomas 
& Tansey, 2011; X. Wang et al., 2011).  
 
MYC is known to be one of the most potent oncogenes that affects multiple cellular processes. 
MYC activation can’t single-handedly initiate tumorigenesis, even though it is one of the most 
frequently activated oncogenes involved in the pathogenesis of human cancers, MYC 
overexpression can’t trigger neoplastic changes on its own, however; its overexpression can be 
highly fatal and carry damaging impact on normal cells, peaking proliferative arrest, senescence 
and/or apoptosis. In other words, Myc pathways evokes cell suicide and cancer (Hoffman & 
Liebermann, 2008; Nilsson & Cleveland, n.d.). This destructive impact of MYC overexpression 
in normal cells also relies on epigenetic and genetic contexts. Additionally, the loss of the tumor 
suppressor p53 coordinate with MYC to trigger cellular growth and tumorigenesis. In 
conclusion, cellular conditions and specific genetic aberrations can facilitate MYC’s capability 
to more readily initiate proliferation and tumorigenesis.  
 
Myc is a pleotropic transcription factor as explained before that affects multiple cellular 
process, it is the downstream target of variable mitogenic pathways. It can force the cell cycle 
advancement in a response to proliferative signals, not only that, but it can actually force cells 
to re-enter the cell cycle. Myc exhibits such controlling effect on the cell cycle as some of the 
crucial positive cell cycle regulators are encoded by genes targeted by Myc ex. cyclins, CDKs 
and E2F transcription factors. Additional to its direct transcriptional activity, it can over activate 
the CDK inhibitor p27 which halts cell cycle progression, p21 is another protein that is inhibited 
by Myc. Therefore, tumor suppressing action by both p53 and p21 is manipulated (Bretones et 
al., 2015; Obaya et al., 1999; Wu et al., 2003).  
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As discussed before that cancer is a multistep process, which means cells gain a series of 
mutations that altogether enhance the activity of proto-oncogenes and represses the tumor 
suppressor gene functions. This results in a heterogenous unleashed tumor cell population 
proliferating, ignoring inhibitor signals. It has been studied that cancer cells depend greatly on 
specific oncogenic mutations for their survival and growth. This is defined as “oncogene 
addiction” (Weinstein & Joe, 2006). This could be explained by the fact that these oncogenes 
frequently have multiplex role in the pathways regulating proliferation and survival of cells and 
initially gave hand in tumor phenotype, this make them regarded as the “Achilles’ heel” of 
cancer cells (Sharma & Settleman, 2007; Weinstein & Joe, 2006). 
 
In neuroblastoma, amplification of N-Myc is seen in almost 20%-25% of cases. When N-Myc 
is amplified, it is often interlinked with high-risk disease and poor prognosis, it is also used as 
the most distinctive genetic marker of risk in neuroblastoma when found. Structurally, both 
MYC and N-Myc are highly homologous in the encoding regions. They also both 
heterodimerize with MAX at consensus E-box sequences. Biologically, N-Myc and MYC are 
remarkably similar in the aspect of encouraging transformation in rat embryo fibroblasts and 
triggering of proliferation and cell cycle advancement in quiescent fibroblasts (Huang & Weiss, 
n.d.). Furthermore, when a deletion of either MYC or N-Myc occurs; normal morphology is 
still achieved, and no irregular proliferation or differentiation compared to the normal state is 
observed. This is probably because MYC and N-Myc can compensate for each other (Huang & 
Weiss, n.d.). 
N-Myc over expression is often correlated with invasive and metastatic behavior, as it is 
involved in all facets of metastasis; adhesion, motility, invasion and break down of surrounding 
matrices (Huang & Weiss, n.d.). 
 
MYC also impacts immunesurveillance by regulating antigens expression tumor cells. One 
example of an antigen repressed by N-Myc is monocyte chemoattractant protein-1/CC 
chemokine ligand 2 (MCP-1/CCL2), essential for chemoattraction of natural kilter T-cell 
(NKT). When N-Myc is knocked down in N-Myc amplified neuroblastoma cell lines, MCP-1 
was revived as well as NKT cell chemoattraction. N-Myc possibly binds to the E-box element 
of the MCP-1 promoter to obstruct the expression of the chemokine (Huang & Weiss, n.d.; 
Song et al., 2007b). 
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2.3.2. Tumor suppressor genes 
 
Tumor suppressor genes or what are known as antioncogenes, are genes which code for proteins 
that obstruct cell proliferation or survival, hence, halting tumor development. However; these 
genes are frequently mutated or inactivated in tumors (Weinberg, 1994). One of the most 
important tumor suppressor genes is the “guardian of the genome” tumor protein p53 is a 
transcription factor and plays crucial role in controlling cell life and death by governing cell 
cycle arrest, senescence, apoptosis, DNA repair and metabolism.  
 
2.3.2.2. Tumor suppressor protein p53 
 
TP53 is located at chromosome 17 (17p13.1).  p53 has numerous and vital roles in cells, the 
p53 network is depicted in figure 4. The multiple functions of p53 are connected to its ability 
to take control over specific sets of its variable target genes. Apart from its role in initiation of 
cell cycle arrest, senescence and apoptosis, p53 is involved in numerous non-canonical 
pathways, such as tissue remodeling, autophagy, metabolism and the control of reactive oxygen 
species (ROS). Seeing how complex and intertwined p53’network is, it is noted that the impact 
of p53 and the impact on p53 are immensely flexible and relies on a collection of factors such 
as the cell type, differentiation state, stresses and influences from the cellular environment 
(Kastenhuber & Lowe, 2017). 
In normal conditions, TP53 gene is regularly transcribed and translated but the protein is then 
degraded by the ubiquitin-dependent system in proteasomes. The degradation of p53 is carried 
out primarily by Mdm2. Mdm2 can also encourage NEDD8 modification of p53, which in turn 
obstructs its transcriptional activity (Xirodimas et al., 2004). Nonetheless, p53 is activated 
stabilized via a course of post-translational modifications as a response to a multiple stress 
signals including DNA damage, oncogene activation, and hypoxia (Giaccia & Kastan, 1998). 
P14ARF is a tumor suppressor protein and it negatively regulates MDM2. Altogether, MDM2, 
p53 and P14ARF construct an autoregulatory loop which is often deregulated in human 
Unfortunately, p53 is found to be defective or inactive in almost all tumors. However, in 
neuroblastoma, p53 is predominantly wild-type, nevertheless; it has been reported that p53 is 
often inactivated through MDM2 amplification or P14ARF irregularities or deletions (Chen & 
Tweddle, 2015). Furthermore, another proposed mechanism for the possible reasoning of non-
functioning p53 in neuroblastoma although the absence of mutations in most cases is through 
the cytoplasmic sequestration such as shielding of the C-terminal nuclear localization signal of 
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p53, defiance against degradation by MDM2, and the possible communication with 
glucocorticoid receptors via binding of BK virus of the polyomavirus family. Another factor 
that might be contributing is that it has been found that conceivably the N-Myc overexpression 
often found in neuroblastoma masks the p21 mediated blockage of the G1 checkpoint resulting 
in unobstructed G1 furtherance (Tweddle et al., 2003). Therefore, there is need for a targeted 
therapies to activate wild-type p53 using p53-Mdm2 antagonists alone or in combination with 
other small molecules to potentially boost survival rate.  
 
2.4. Small molecules used in our study 
 
In our study, we are using three different compounds, MYCMI-6, Nutlin-3 and Atsp7041. 
MYCMI-6 is a powerful selective inhibitor of MYC:MAX interaction in cells (Castell, Yan, 
Fawkner, Hydbring, et al., 2018a). It blocks MYC-driven transcription and binds selectively to 
the MYC bHLHZip domain, therefore; it blocks tumor cell growth in a MYC-dependent 
manner, as well as MYC:MAX interaction, represses proliferation and triggers extensive 
apoptosis in tumor tissue in a MYC-driven xenograft tumor model without implying serious 
side effects (Castell, Yan, Fawkner, Hydbring, et al., 2018b). Nutlin-3 is a characterized MDM2 
inhibitor small molecule which hinder the p53-binding domain of MDM2, hence; p53 is 
stabilized and activated (Nutlin 3 - an overview | ScienceDirect Topics, n.d.).  ATSP-7041 is a 
stapled α-helical short peptide that potently and selectively dual inhibitor of MDM2 and 
MDMX. It effectively stimulates the p53 pathway in tumors both in vivo and in vitro (Chang et 
al., 2013b). 
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Figure 4: Interactions within the p53 network. Both canonical and non-canonical pathways are shown 
(Kastenhuber & Lowe, 2017) 
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3. Aim of the project 
 
Neuroblastoma  is the most common extracranial solid tumor occurring in infants and children 
comprising around 8%-10% of all childhood tumors. Despite intensive multimodal therapy, 
high-risk neuroblastoma leads to fatal clinical outcome, around 15% of all deaths due to 
neuroblastoma is in the pediatric sector (Park et al., 2010). Therefore, there is a powerful 
necessity to identify and establish novel targeted strategies that modulate genes with central 
roles in tumor progression.  
 
In our project, we are trying to investigate and showcase the effect of molecules that inhibit 
MYC and activate p53 on activation of the tumor immunogenicity, hence, tumor regression in 
neuroblastoma. Neuroblastoma cells exhibit tumor-associated antigens however, it has 
deficiency in the expression of costimulatory molecules and HLA class-I and II molecules 
(Prigione et al., 2004). Therefore, neuroblastoma cells are seemingly overlooked by the host T-
cell compartment, due to the insufficient expression of HLA and costimulatory molecules on 
antigen presenting cells, which in turn are crucial for effective peptide presentation to T cells 
(Prigione et al., 2004). In this study, we tried to get a better understanding of the innate immune 
response by inhibition of N-Myc using MYCMI-6 and activation of p53 using ATSP-7041 and 
Nutlin-3.  
 
We focused on Atsp-7041 p53-activating and MYCMI-6 MYC-inhibitor small molecules to 
study the changes they embody on the tumor immunogenicity cascade in neuroblastoma cell 
lines, possibly leading as a result to tumor regression.   
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4. Materials and Methods 
 
4.1. Cell Culture 
 
The Cell lines used in my experiments were provided by Dr. Madhurendra Singh and Dr. Ali 
Rihani. All cell lines except IMR-32 were cultured and maintained in Dulbecco’s modified 
Eagle medium/high glucose (DMEM; Gibco). The cell line IMR-32 was maintained in RPMI-
1640 (Hyclone). Both mediums were supplemented with 10% v/v fetal bovine serum (FBS; 
Thermo Scientific) and 100g/mL penicillin/streptomycin (Thermo Scientific) referred as 
complete media, the cells were incubated at 37°C with 5% CO2.  Contaminations with 
mycoplasma were frequently tested.  
 
Table 1. Materials used in cell culture 
Component Source Catalogue number 
DMEM (High glucose) Gibco 41965-039 
RPMI-1640 Hyclone SH30027.01 
FBS Thermo Fischer scientific   
PBS Gibco   
Trypsin-EDTA Sigma-Aldrich  
DMSO Sigma D8418 
Resazurin Sigma R7017-6 
 
Table 2. Cell lines used (Tom Van Maerken et al., 2011) 
Cell line name Properties 
SK-N-FI P53: mutant 
MYCN: non-amplified 
SKNDZ P53: mutant 
MYCN: amplified 
SK-N-BE(2c) P53: mutant 
MYCN: amplified 
IMR-32 P53: wild type 
MYCN: amplified 
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SH-SY5Y P53: wild type 
MYCN: non-amplified 
SK-N-AS P53: mutant 
MYCN: non-amplified 
C-MYC gain 
 
4.2. Cell Passage 
 
Cells were passaged when reaching 70-80% confluency. The cells were washed, one time with 
sterile 1xPBS, then incubated in 1X Trypsin-EDTA for 2-3 minutes at 37C incubator. After 
thorough checking under the microscope to ensure detachment of the cells, trypsin was 
inactivated using 9 mL of complete medium.  
 
4.3. Cell Counting 
 
A sample of the cells is thoroughly mixed with 0.4% Trypan Blue (Life technologies) in ratio 
of 1:1, and 10L transferred to a hemocytometer counting chamber, then counted manually. 
The required number of cells were then cultured again in fresh plates, already supplied with 
fresh media. For the 6-well plates, we have used 100,000-200,000 cells per well in 2mL. For 
the 6-cm plates, 0.5 million cells per plate in 3mL were seeded, and for the 96-well plates, 5000 
cells per well in 0.1 mL complete media.  
 
4.4. Compounds treatment 
 
For qPCR and Western blot, one day before treatment cells were seeded in either 6-well or 6-
cm dish. The concentration was used as IC50 of each compound determined by resazurin assay.  
 
Table 3. Conditions of treatment and combinations 
Conditions Compounds Concentration (in µM) 
1 DMSO (control)  0.1% 
2 MI-6 2 
3 ATSP-7041 1 
4 MI-6 & 7041 2 + 1 
5 Nutlin-3 1 
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6 MI-6 & Nutlin-3 2 + 1 
 
The cells were treated at two time points, 8 hours and 16 hours under the same conditions in 
the incubator.  
 
4.5. Cell Viability using Resazurin Assay 
 
Resazurin is a cell permeable redox indicator that was used to examine the viability of the cells 
following compounds. Since, viable cells with active metabolism can reduce resazurin into the 
pink and fluorescent resorufin product, and the quantity of the produced resorufin is 
proportionate with the viable cells. Hence, the most convenient concentration of compounds 
with a minimal side effects on cell viability can be determined, after quantifying of the resorufin 
using a microplate fluorometer equipped with a 560 nm excitation / 590 nm emission filter. The 
assay was performed in 96-well plates. On the following day, the cells were treated with the 
compounds in two-fold serial dilution as mentioned in figure legends. At the corresponding 
treatment time point, the existing media is supplemented with 5µM final concentration of 
resazurin in complete medium. After two hours of incubation, the fluorescence intensity was 
quantified and IC50 for each treatment was determined using Microsoft Excel 2007. 
 
4.6. RNA extraction and Complementary DNA synthesis (cDNA) 
 
4.6.1. RNA extraction using TRIzol reagent (Invitrogen, catalogue number: 15596026) 
 
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other 
proprietary components which enable the isolation of various RNA with variable sizes.  
Isolation of RNA was performed using this method, to isolate the small RNAs. The protocol 
followed was supplied by Invitrogen for the TRIzol reagent. Before harvesting, the treated cells 
were washed with 1X PBS and 400 µL of TRIzol was added in each well and cell lysates were 
collected by scraping and total RNA was isolated according to standard procedure. 
Table 4. Concentrations of treatment  
Compound Concentration µM 
MI-6 2 
7041 1 
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Nutlin 1 
 
DMSO was used as a control, its concentration was set based on the highest volume of 
combination treatment used. Before harvesting, the old media was removed, and the cells were 
washed with ice-cold PBS, which was also removed.  
A cell scraper was used to collect cells from the 6-well plate using the TRIzol reagent.   
 
4.6.2. RNA extraction using Bio-Rad kit (Catalogue number: 732-6820) 
 
Another method used for RNA extraction was the Aurum Total RNA Mini kit by Bio-Rad.  
Cells were seeded and treated as mentioned previously. The adherent cell cultures were 
harvested using lysis solution (supplemented with 1% ß-mercaptoethanol) into provided tubes, 
the cells were left with the lysis solution on the shaker for 15 mins before scraping into tubes. 
Scraping of the cells was followed by addition of 70% ethanol, mixed thoroughly assuring 
decreased viscosity and loss of bilayer. All the homogenized lysates were transferred to an RNA 
binding column, and centrifuged at 12,000rcf for 30 seconds at room temperature. Flow-
through was discarded, and low stringency solution was added (from kit, supplemented with 
80ml absolute ethanol). Once more, the tubes were centrifuged and flow-through discarded. 
The tubes were incubated at room temperature for 15 minutes in RNase-free DNase I 
(reconstituted by 10mM Tris, pH 7.5, and diluted by DNase dilution solution provided 1:15). 
After incubation, high stringency solution was added for washing (provided by the kit), 
centrifuged for 30 seconds and flow-through discarded. The cells were washed once more with 
the low stringency solution, centrifuged for 1 minute and flow-through discarded. To ensure 
complete removal of wash solutions as ethanol can inhibit down-stream reactions, the tubes 
were centrifuged for an additional 2 minutes. For elution of the purified RNA, in fresh 
Eppendorf tubes, elution buffer (supplied by the kit) was pipetted on the membrane stack at the 
bottom of the RNA binding column, left to saturate for 1 minute, then centrifuged for 2 minutes 
to recover the isolated RNA.  
 
4.7. Complementary DNA (cDNA) synthesis 
 
Following RNA isolation, the concentrations of the RNA was measured using the NanoDrop 
2000 device (Thermo Scientific), using the elution buffer from the kit as a blank. 1µg of total 
RNA was equalized to 16µL using nuclease free water (Qiagen). Finally, 4µl of the master mix 
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Bio-Rad (5x iScript Reaction Mix + iScript Reverse transcriptase, iScript cDNA synthesis kit, 
Bio-Rad) was added in each 16 µL RNA. 
The resulting cDNA was 50ng/µl in each tube.  
 
Table 5. c-DNA synthesis program used 
Steps Temperature (°C)  Time (Minutes) 
Priming 25 5 
Reverse Transcription 
(RT) 
42 30 
RT inactivation 85 5 
 
Subsequent successful cDNA synthesis, cDNA was diluted by adding 170µl nuclease-free 
water, and 10µl of 40x Yellow RNA Loading Dye to make total volume 200µL and 
concentration of cDNA 5 ng/µL. 
 
4.8. Gene Expression Analysis by Quantitative real-time Polymerase Chain Reaction 
(qRT-PCR) 
 
100 µM each Gene specific forward and reverse primer stock solutions were diluted in NFW 
to reach the final concentration of a 5µM final each primer. A mastermix of the primers and 
SsoAdvanced Universal SYBR green supermix (pre-supplemented with 55 µl of Precision Blue 
Real-Time PCR dye) was then prepared for each gene, where 2.5µl of SsoAdvanced Universal 
SYBR green was mixed with 0.5µl of the working solution of the primers previously prepared.  
 
In a 384-well plate, 3µl of the mastermix was pipetted in the each well, then 2µl (10 ng) of the 
cDNA pipetted in triplicates pattern in each corresponding well. And run according to the given 
program (Table 6). 
Housekeeping genes were GAPDH, RPLP0, RPL13A, TBP, ACTB, HPRT1, B2M and 
YWAH1 
The sequence of the primers of the genes used in qRT-PCR were reported in this study (Castell, 
Yan, Fawkner, Hydbring, et al., 2018a; Sheng et al., 2018). 
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Table 6. Quantitative Real-Time Polymerase Chain Reaction program 
Steps Temperature (°C) Time (Minutes)  
1 Initial Denaturation 95 2:00 - 
2 Final Denaturation 95 0:10  - 
3 Annealing 6 0:45  
4 - - Plateread 
5 - - Steps 2-4 repeated 
40x 
6 Melting curve 65 0:31  
7 65 0:05 + 0,5°C/cycle 
Ramp 0,5°C C/s 
8 -  Plateread 
9 -  Steps 7-8 repeated 
60x 
 
4.9. Western Blot Analysis 
 
4.9.1. Cells harvesting and Protein isolation 
 
Cells were seeded in 6 cm dishes and harvested and lysed using 200 µL RIPA buffer 
(supplemented with protease inhibitor cocktail, cOmplete ref: 11697498001, Roche, and 
phosphatase inhibitor, PhosSTOP, Ref: 04906837001, Roche). The cells were scrapped in 
RIPA buffer on ice and collected in pre-chilled 1.5 mL eppendorf tubes. Lysates were incubated 
on ice for 30 minutes, while briefly and gently vortexing every 10 minutes. Following the 30-
minute incubation time, samples were centrifuged at 13,200 rpm for 15 minutes at 4°C. In pre-
chilled eppendorf tubes, the supernatant was collected and stored at -80°C for further analysis 
 
4.9.2. Protein quantification 
The protein quantification was carried out using the Pierce BCA Protein Assay Kit (Thermo 
Scientific, Ref: 23225). ), according to standard procedure. Bovine Serum albumin (BSA, 
ThermoScientific, 2mg/mL) was used to plot standard curve. The BSA concentrations was 0.5, 
1, 1.5, 2, 2.5, 3, 5 and 7 µg/µL used in duplicate in 96 well plate. While 1µl of each sample per 
well was used. Following a 30-minute incubation at 37°C, the absorbance at 568 nm was 
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measured using Victor X3 multilabel plate reader (PerkinElmer). The results of the protein 
quantification were then analyzed and plotted against a linear standard curve of the albumin 
standard using Microsoft Excel 2007.  
Equal volume of protein samples was prepared by addition of 6x Laemmli buffer (provided by 
Dr. Madhurendra Singh) and heated at 95 C for 5 minutes. 
 
4.9.3. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
A sodium dodecyl sulfate polyacrylamide separating gel and stacking gel were prepared (Table 
7) and assembled in the electrophoresis apparatus. The samples and Pageruler Prestained 
protein ladder (Thermo Scientific) were loaded and ran at 100V for approximately 2 hours.  
 
Table 7. Chemicals used for preparation of the SDS-PAGE Gel 
Components  Volume for 
Resolving gel (12.5 
%, 1x)  
Volume for 
Resolving gel (7.5 
%, 1x)  
Volume for 
Stacking gel 
(1x)  
Acrylamid/Bis (30%) 2.5 mL  1 mL  0.3 mL  
Resolving gel buffer (pH 
8,8) 
3 mL  3 mL  -  
Stacking gel buffer (pH 6,8) -  -  1.5 mL  
dH2O  0.5 mL  2 mL  1.25 mL  
N,N,N’,N’-Tetramethyl- 
ethylenediamine (TEMED) 
15 μL  15 μL  10 μL  
APS (10 %)  45 μL  45 μL  20 μL  
 
 
4.9.4. Wet Transfer 
 
Following electrophoresis, the gel is wet transferred onto a 0.45 micron nitrocellulose 
membrane (GE Healthcare Life Sciences). A typical wet transfer sandwich was constructed 
consisting of the following in order; one foam, 2 Whatman filter papers, the gel, a nitrocellulose 
membrane, 2 Whatman filter paper, finalized by another foam. The transfer cassette and the 
nitrocellulose membrane, and all the sandwich-components were pre-soaked in 1x Transfer 
buffer (1x Tris-glycine transfer buffer, 20% absolute Ethanol and distilled water). After 
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assembly of the transfer cassette and the ice-block, the chamber was filled to the fullest with 1x 
transfer buffer, ran at 30V overnight.  
On the next day, the membrane was washed thrice with 1X PBS-T (1x PBS, and 0,1% Tween-
20). The membrane was stained by Ponceau S solution to rapidly detect transfer of the proteins, 
before blocking with 5% non-fat dried milk (PanReac AppliChem) in 1X PBS-T at room 
temperature for 1 hour. The milk blocking solution was used for all antibodies except for the 
phoshoSTAT1, where it was blocked in 5% bovine serum albumin (BSA, Sigma-Aldrich) in 
1x PBST. After blocking the membrane was incubated with the primary antibody (shown in 
Table 8) in blocking solution overnight at 4C cold-room.  
On the following day, the membrane was washed, thrice with 1x PBS-T, and incubated for 2 
hours at room temperature in the corresponding HRP-coupled secondary antibody (diluted in 
5% milk). Subsequent the incubation in the secondary antibody, the membrane was developed 
using the SuperSignal West Dura Luminol/Enhancer solution and the SuperSignal West Dura 
Stable Peroxide buffer (Thermo Scientific) mixed 1:1, in the Bio-Rad Imager with Gel-Doc 
software.  
 
Table 8. Antibodies used in Western Blot analysis 
Antibody Origin Company Dilutions 
c-Myc (Y69) Rabbit  Abcam 1:500 
N-Myc (SC-53993) Mouse Santa Cruz 
biotechnology 
1:500 
P53 (DO-1, SC-126) Mouse Santa Cruz 
biotechnology 
1:1000 
P21 (Cip1, 610234) Mouse BD biosciences 1:500 
ISG-15 (SC-166755) Mouse Santa Cruz 
biotechnology 
1:500 
DNMT1 (ab13537) Mouse Abcam  1:500 
pSTAT1 (Y701, 
9167)  
Rabbit Cell Signalling 
Technology 
1:500 
 
STAT1 (9172T) Rabbit Cell Signalling 
Technology 
1:500 
β-Actin Mouse Millipore 1:10,000 
 
 
30 
Anti-mouse HRP 
coupled secondary 
antibody 
Goat Jackson 1:5000 
Anti-rabbit HRP 
coupled secondary 
antibody 
Goat Jackson 1:5000 
 
4.10. Flow Cytometry analysis 
 
To investigate the interferon signaling after compounds treatment, the cell lines were 
transduced with ISRE-mCherry lentivirus (supplied by Dr. Madhurendra Singh). The 
transduced cells were seeded in 6 cm dishes and treated with MI-6, Nutlin-3 and 7041 using 
the same conditions mentioned in tables 3 and 4. After 18 hours, the cells were washed, 
trypsinized and collected in 5 mL FACS tubes. The mCherry intensity was measured using 
FACS Calibur Flow Cytometer (BD Biosciences) and analysis were done using BD CellQuest 
software.  
 
4.11. Generation of p53-deficient IMR-32 cells using CRISPR-Cpf1 
The cell lines were prepared by Dr. Madhurendra Singh. The generation of p53 knockouts was 
performed using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR- 
associated (CRISP/Cas 12a, also known as AsCpf1) (Bin Moon et al., 2018; Gao et al., 2016).   
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5. Results 
 
5.1. N-Myc inhibition and p53-reactivation by co-treatment have additive effects on 
neuroblastoma growth suppression 
 
We wanted to determine the LD50 (Lethal Dose 50%)2 where the cells are 50% dead when we 
treat with the molecules. To achieve this we used resazurin viability assay using two-fold serial 
dilutions of the compounds in neuroblastoma cell lines (p53 WT; N-Myc non-amplified – 
SHSY-5Y, p53 WT; N-Myc amplified – IMR32, p53 mutant; N-Myc non-amplified – SKNAS 
while MI-6 showed reduced growth suppression only in N-Myc amplified cell lines at lower 
concentration. While N-Myc non-amplified cells had growth suppression at mid -high 
concentration (2.5 uM). The p53 mutant cells showed minimal or no growth suppression by 
p53-WT reactivating compound (Fig. 5C and D).  
In MI-6 and 7041 combination treatment, all cell lines showed either enhance (SHSY-5Y) or 
like alone single compound treatment (Fig. 5B-D) growth suppression. Based on these 
experiment we have chosen SHSY-5Y and IMR-32 using 1 M of 7041 and 2 M of MI-6 for 
further experiments. and p53 mutant ; N-Myc amplified SK-BE2) (Fig.5). In p53-WT cells, 
SH-SY5Y (5A) and IMR32 (5B), alone 7041 treatment have drastic growth suppression at 
lower concentration, 
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5.2. Validation of p53 and MYC target genes expression using compounds treatment in 
neuroblastoma 
 
Next, we verified the compounds activity in cells by monitoring their target-regulated gene 
expression at mRNA and at protein levels (Fig. 6). To verify MI-6 dependent N-Myc inhibition, 
we have chosen N-Myc regulated genes - GLUT1, HK2, CAD, TPI1, PFKM, c-Myc and N-
Myc (Castell, Yan, Fawkner, Zhang, et al., 2018). And as p53 repress Myc expression, c-MYC 
and N-MYC were used to verify p53-dependent 7041 or nutlin activity. 
All genes were downregulated following treatment; however, Nutlin-3 showed the least 
efficacy, while MI6&7041 was the most effective treatment condition in almost all genes.  
Figure 5: Cell viability using Resazurin assay in four different neuroblastoma cell lines; SH-SY5Y, IMR-
32, SK-N-AS and SK-BE2. All the cells were treated with MI-6, 7041 and combination of MI-6&7041, in 
two-fold serial dilution. The serial dilution was as follows: 10M, 5M, 2.5M, 1.25M, 0M (DMSO). A) 
SH-SY5Y cell line, the cells were treated for 24 hours. B) IMR-32 cell line, the cells were treated for 16 hours. 
C) SK-N-AS cell line, the cells were treated for 24 hours. D) SK-BE2 cell line, the cells were treated for 24 
hours. The x-axes in all charts show: concentration of compounds in M, while the y-axes show % of viable 
cells (normalized to DMSO treated cells.) The error bars represent the SD.  
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Nevertheless, in IMR-32 (Fig. 6C), treatment was less effective than in other cell lines, which 
suggests that 8 hours is less effective than 16-hour treatment time point. Western blot analysis 
for SH-SY5Y (Fig. 6B) and IMR-32 (Fig. 6D) cell lines was then performed to examine the 
protein levels of the N-Myc, c-Myc, p53 and p21, to validate the qPCR results. The same 
treatment conditions with the same concentrations were followed.  
In SH-SY5Y, N-Myc protein level showed extreme downregulation in MI-6 treatment, and 
slight down regulation in MI-6&7041 and MI6&Nutlin-3 treatment. In addition, c-Myc was 
down regulated slightly after treatment of MI-6&7041. While p53 and p21 protein levels were 
highly upregulated after treatment with 7041 and combination, and slightly upregulated after 
treatment with Nutlin-3 and MI-6&Nutlin-3. 
In IMR-32 cell line, c-Myc protein level was slightly downregulated following treatment, N-
Myc was marginally downregulated subsequent MI-6&Nutlin treatment, while p53 and p21 
were remarkably upregulated after treatment with 7041 and MI6&7041. On the contrary, p53 
and p21 protein levels were upregulated but with less intensity under Nutin-3 and Nutlin-
3&MI6 treatment conditions, in comparison to 7041.  
Concluding that, the compounds under study are functioning adequately. Therefore, we 
proceeded with investigating the effect of p53 and N-Myc on the tumor immunogenicity.  
 
5.3. Antigen processing and presentation genes upregulation after p53 activation and Myc 
inhibition in SY5Y and IMR32 cells.  
 
The antigen and processing cells will express MHC class I loaded with antigen to get recognize 
by T cells. It is a process where protein antigen is endocytosed by an antigen-presenting cell 
(APC), broken down into peptide fragments and presented on the surface of the APC with an 
antigen-presenting molecule such as MHC class I or MHC class II. Some of those antigen 
processing and presenting genes include 2M, ERAP1, ERAP2, TAP1, TAP2, MHC class I 
(HLA-A, HLA-B, HLA-C) (Mak et al., 2014). Also as previously mentioned that, the host T-
cell compartment evidently turn a blind eye to neuroblastoma cells due to the limited expression 
of HLA and costimulatory molecules on antigen presenting cells, which as we discussed are 
consequential for effective peptide presentation to T cells (Prigione et al., 2004). 
Therefore, the genes involved in antigen processing and presentation were examined using 
qPCR in SH-SY5Y (Fig.7) and IMR-32 (Fig.8). After treatment of the cells with MI-6, 7041, 
and combination, in SH-SY5Y, HLA-B (1.8 fold), HLA-C (1.8-fold), 2M (1.6-fold), TAP1 
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(7-fold), TAPBP1 (1.2-fold) and ERAP2 (1.8-fold) were upregulated in comparison to DMSO-
treated cells. Additionally, in IMR-32 p53 wild-type cells, these genes HLA-B (1.4-fold), HLA-
C (1.7-fold), 2M (1.7-fold), TAP1 (2-fold), TAPBP1 (1.9-fold), ERAP1 (1.8-fold) and 
ERAP2 (1.6-fold) were upregulated when compared to DMSO-treated cells under the same 
conditions. In IMR-32, all the antigen processing presentation genes were p53 dependent, as 
the upregulation of most genes were absent in p53-KO cells after treatments.  
 
5.4. Induction of anti-viral Type I Interferon beta after p53 activation and N-Myc 
inhibition 
 
Since tumor cells behave similarly to virus-infected cells, they radiate danger signals to warrant 
immune system, type-I interferons have a lead role for the following events linking innate and 
cognate immunity (Sistigu et al., 2014). Furthermore, it has been proposed that the MHC-class 
I processing and presentation genes are under control of JAK-STAT signaling (Goel et al., 
2017). Also, type-I-IFNs forms a bond with a heterodimeric transmembrane receptor called 
IFN-/ receptor (IFNAR) which activates JAK-STAT signaling. As a result, the transcription 
of numerous IFN-stimulated genes’ (ISGs) is triggered. On the grounds of these findings, the 
levels of type-I interferon were a point of interest in our experiment.  
 
Therefore, first we have established Interferon-reporter assay using 8x ISRE-mCherry in IMR-
32 and SHSY-5Y cells (Fig.9), the ISRE Reporter is designed for monitoring the activity of 
Type I interferon-induced JAK/STAT signaling pathway in the cultured cells. 
In both cell lines, single treatment of 7041, Nutlin or MI-6 have minimal activation of interferon 
signaling, while combination of p53-activation and Myc-inhibition have significantly increased 
mCherry expression as monitored by flow cytometry.  
To further validate this finding, we checked the gene expression levels of Interferons and 
Interferon-regulated genes. Interestingly, Type I INF- was significantly induced (Fig. 10A) 
after combination. Moreover, the INF-β upstream transcription factor IRF7 was also 
significantly induced. Which suggest that Interferon signaling is induced after combination 
treatment. To strengthen our finding, we also performed INF-β regulated genes IFN-28A and 
ISG56. We found those were significantly induced after N-Myc inhibition and p53 activation. 
We did not observe changes in other genes it is might because of technical issue, due to time 
limitation I was unable to perform more experiments. 
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Furthermore, on protein level we could observe induction of phosphoSTAT1 and ISG-15 in 
IMR-32 cells (Fig. 10B). Which confirm our finding that combination treatment has enhance 
anti-viral innate immune response. 
 
 
 
 
 
               Figure 6: Confirmation of the compounds activity. Each cell lines were seeded in 6-well plates. The 
same treatment pattern was followed; DMSO (black), MI-6 (2M, blue), 7041 (1M, red), MI-6&7041 
(green), Nutlin-3 (1M, red-coloured with pattern fill) and MI-6& Nutlin-3 (blue coloured with pattern 
fill). A) SH-SY5Y cell line qPCR analysis showing the RNA expression levels of the genes after 
treatment for 16h. y-axes show fold change B) Western blot analysis for SH-SY5Y showing N-Myc (70 
kDa), c-Myc (70 kDa), p53 (53 kDa), and p21 (21 kDa) protein levels after treatment. -actin (42 kDa) 
was used as a loading control. C) IMR-32 cell line qPCR analysis showing the RNA expression levels of 
the control genes. The cells were treated for 8 hours. Y-axes show fold change D) Western blot analysis 
for IMR-32 showing protein levels of N-Myc, c-Myc, p53 and p21. -actin was used as a loading control. 
All experiments were performed n=1 
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Figure 7: Antigen processing and presentation genes upregulation after p53 activation and Myc inhibition in SH-
SHSY-5Y. qPCR analysis was performed to check the RNA expression levels of the MHC class genes. Treatment 
conditions were DMSO, MI-6 (2M, blue-coloured), 7041 (1M, red-coloured) and MI-6 and 7041 (green-coloured) 
for 16 hours. Each bar represents the mean with the standard error of mean (SEM) of at least two experiments. P-values 
were calculated by one-way ANOVA test and differences in gene regulation between treatment were compared using 
post-hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). The real-time qPCR presented as 
fold changes of gene expression compared to DMSO.  
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Figure 8: p53-depepndent antigen processing and presentation genes upregulation in IMR-32 cells. qPCR analysis 
was performed to check the RNA expression levels of the MHC class genes. Treatment conditions were DMSO, MI-6 
(2M, blue-coloured), 7041 (1M, red-coloured) and MI-6 and 7041 (green-coloured) for 16 hours. The p53 wild-type 
cells are solid-filled while the p53 knockouts are pattern filled.   
Each bar represents the mean with the standard error of mean (SEM) of at least two independents experiments. P-values 
were calculated by one-way ANOVA test and differences in gene regulation between treatment were compared using post-
hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). The data presented as fold changes of gene 
expression compared to DMSO.  
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Figure 9: Induction of Interferon signaling after successive treatment with the molecules in SH-SY5Y and IMR-32 
neuroblastoma cell lines. A) Interferon signaling in SH-SY5Y after 16hr treatment with DMSO (grey-coloured), MI-6 (2M, 
green coloured), 7041(1M, red coloured) and combination of these two small molecules (blue-coloured). B) Interferon 
signaling in SH-SY5Y after 16hr treatment with DMSO, MI-6 (2M), Nutlin-3 (1M, red-coloured) and combination of these 
two small molecules (blue-coloured). C) Interferon signaling in IMR-32 after 18hr treatment with DMSO, MI-6, 7041 and 
combination of these two molecules. D) Interferon signaling in IMR-32 after 18hr treatment with DMSO, MI-6, Nutlin-3 and 
combination of these two small molecules. Experiments were performed n=2  
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Figure 10: Induction of interferon-signaling after combination treatment in SH-SY5Y neuroblastoma cell line. A) 
qPCR analysis was performed to check the RNA expression levels of the STAT/IFN pathway genes, the second 
checkpoint. Treatment conditions were DMSO, MI-6 (2M, blue-coloured), 7041 (1M, red-coloured) and MI-6 and 
7041 (green-coloured) for 16 hours. Each bar represents the mean with the standard error of mean (SEM) of at least two 
experiments. P-values were calculated by one-way ANOVA test and differences in gene regulation between treatment 
were compared using post-hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).  
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Figure 11: Induction of interferon-signaling after combination treatment in SH-SY5Y neuroblastoma cell 
line in IMR-32 neuroblastoma cell line. A) qPCR analysis was performed to check the RNA expression levels 
of the STAT/IFN pathway genes. Treatment conditions were DMSO, MI-6 (2M, blue-coloured), 7041 (1M, 
red-coloured) and MI-6 and 7041 (green-coloured) for 16 hours. The p53 wild-type cells are solid-filled while 
the p53 knockouts are pattern filled. Each bar represents the mean with the standard error of mean (SEM) of at 
least two experiments. P-values were calculated by one-way ANOVA test and differences in gene regulation 
between treatment were compared using post-hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001). B) Protein level of ISG-15 and pSTAT1 after treatments for 18 hours. 
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5.5. Induction of endogenous retroviruses (ERVs) and dsRNA receptor after combination 
treatments 
The concept of immunoediting as previously mentioned hypothesize that cancer cells has the 
capability to wind down immunogenicity to circumvent destruction by the host’s immune 
system. Endogenous retroviruses are retroviruses that are present in the human genome (around  
8% of the human genome) although it is almost majorly silenced epigenetically including DNA 
methylation via Dnmt1 in the CpG sites or by deactivating mutations. It has been found that 
when ERVs are activated or their expression is elevated in human cells, an immune response is 
initiated through the awakening of innate and adaptive immunity (Gonzalez-Cao et al., 2016).  
 
Previous literature has demonstrated that DNA methyltransferase inhibitors (DNMTi) elevate 
immune response in tumor via a viral defense channel. DNMTi tend to activate cytosolic 
sensing of double-stranded RNA (dsRNA) which in turn triggers a Type I interferon response 
and cell death. When ERVs are upregulated or overly expressed, they further trigger the 
interferon response as mentioned above (Chiappinelli et al., 2015). It has also been shown that 
5-Aza-deoxycytidine (DNMTi) activates p53 signaling, consequently apoptosis is triggered. 
This proposes that the DNA methylation action exerted by DNMTs is linked to p53 signaling 
(Y. A. Wang et al., 2005). Another study has validated that p53 and RB genes transcriptionally 
inhibit DNMT expression (Tang et al., n.d.), thus, ERVs are activated in consequence.  
 
Accordingly, the third checkpoint we wanted to study the effect of our treatment on, after 
proving successful effectiveness on the first two checkpoints, was the induction of ERVs. qPCR 
analysis was performed to check the RNA expression levels of different ERVs in SH-SY5Y 
(Fig. 12) and IMR-32 (Fig. 13).  
 
The ERVs tested using qPCR were: ERV-E, ERV-F, ERV-K, ERV-L, ERV-WE1 envelope 
protein, ERV-WE1, LTR26E, and ERV3 envelope protein. Some of these were not expressed 
in our model cell lines, and others were not significantly changed.  
 
The gene expression levels of SH-SY5Y showed induction in ERV K, ERV E, ERV L, ERV 
WE1, ERV WE1 envelope protein, and in long terminal repeat 26E (LTR26E). Furthermore. 
IMR-32 cells showed upregulation in ERV E, ERV K and ERV3 envelope protein. In this cell 
line, the dependency on p53 activation was proven, as the p53 knocked-down cells showed 
contrast results to the p53 wild-type cells. This data suggests the advantageous and successful 
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activation of the third checkpoint of the pathway, by the reason of induction of RNA expression 
levels of ERVs following treatment with MI-6 and 7041. . The ERVs can transcribe bi-
directionally by both sense and anti-sense strand of DNA and thus form dsRNA in the 
cytoplasm. The ERVs in cytoplasm can be recognized by the dsRNA sensors: TLR3, MDA5 
and RIG-1 and transduce the signal to MAVS (Chiappinelli et al., 2015). Moreover, we could 
see significant induction of TLR3, MAVS and RIG-1 after combination treatment. These results 
confirm the induction of ERVs dictate type I interferon signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Induction of endogenous retroviruses (ERVs) and dsRNA receptor after combination treatment in 
SH-SY5Y. qPCR analysis was performed to test the effect of treatment on the RNA expression levels of ERVs. 
Treatment conditions were DMSO, MI-6 (2M, blue-coloured), 7041 (1M, red-coloured) and MI-6 and 7041 (green-
coloured) for 16 hours. Each bar represents the mean with the standard error of mean (SEM) of at least two independents 
experiments. P-values were calculated by one-way ANOVA test and differences in gene regulation between treatment 
were compared using post-hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).  
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Figure 13: p53-dependent induction of endogenous retroviruses (ERVs) and dsRNA receptor after 
combination treatment in IMR-32. qPCR analysis was carried-out to test the effect of treatment on the RNA 
expression levels of ERVs. Treatment conditions were DMSO, MI-6 (2M, blue-coloured), 7041 (1M, red-
coloured) and MI-6 and 7041 (green-coloured) for 16 hours. The p53 wild-type cells are solid-filled while the p53 
knockouts are pattern filled. Each bar represents the mean with the standard error of mean (SEM) of at least two 
experiments. P-values were calculated by one-way ANOVA test and differences in gene regulation between 
treatment were compared using post-hoc Fisher’s LSD test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
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5.6. DNMT-1 repression after combination treatment responsible for observed ERVs 
expression 
 
As mentioned before, the ERVs promoter are highly methylated and their expression is silenced 
(Chiappinelli et al., 2015). We hypothesized that the upregulation of ERVs is might due to 
repression of DNMT1 by inhibition of MYC and activation of p53.  
To validate this hypothesis, we checked the mRNA and protein expression of DNMT1 after 
compounds treatment. Indeed, the mRNA expression of DNMT1 (Fig. 14A and C) in both cell 
lines were significantly reduced after combination treatment. Moreover, at DNMT1 protein 
level, combination showed more reduction (Fig. 14B and D). 
Taken together, our result suggest the p53 activation and Myc repression in neuroblastoma 
leads to repression of DNMT1 at ERVs promoter which leads to expression and accumulation 
of dsRNA stress and Type I interferon signaling mediated induction of tumor immunogenicity 
(Figure 15). 
 
  A 
 
B 
Figure 14: DNMT1 down regulation after combination treatment. A) qPCR analysis was performed 
to check the RNA expression levels of DNMT-1 after treatment in SY5Y B) Western blot analysis for SH-
SY5Y showing protein levels of DNMT-1 following treatment with MI-6 and 7041. -actin was used as a 
loading control (Shown in fig. 5B). C) qPCR analysis was performed to check the RNA expression levels 
of  DNMT-1 after treatment in IMR-32 D) Western blot analysis for IMR-32 showing protein levels of 
DNMT-1 following treatment with MI-6 and 7041. The same treatment conditions were followed in both 
qPCR and western blot analysis. Experiment n=2 
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6. Discussion 
To eliminate cancer, we need to fully activate the host immune system, which has the capacity 
to distinguish self and non-self-antigens. The tumor p53 have shown to function as an important 
activator of innate immunity (Sanz et al., 2019). In contrast oncogene Myc have opposing 
function in both innate and adaptive immunity. In this project, we try to address important 
question: does p53-activation and Myc-inhibition in neuroblastoma leads to increased tumor 
immunogenicity?  
Our findings suggests, 1) combination of MYC inhibitor and p53-activators lead to increased 
expression of antigen processing and presentation genes 2) the enhanced activation of antigen 
processing and presentation genes is due to increased anti-viral type I interferon beta signaling. 
3) the expression and production of INF- is under control of ERVs derived dsRNA production 
and their binding to dsRNA sensors in the cells 4) the inhibition of DNA (cytosine-5)-
methyltransferase 1 is an enzyme, DNMT1 after combination might be responsible for observed 
enhanced expression of ERVs and down-stream signaling cascade.  
 
TP53 is a gene that codes for a p53 protein that governs numerous pathways such as metabolic 
reprogramming, autophagy, cell cycle arrest and apoptosis. It is a master regulator for cells and 
has pivotal role in multicellular organisms to suppress cancer; however, it is often found 
mutated or inactivated. Furthermore, through previous literature showing an intact p53 
pathway, it has been recently shown or evidenced that p53 inactivation might be the remarkable 
mechanism of drug resistance found in neuroblastoma cell lines to date. The study of p53 in 
neuroblastoma has emerged some observations of p53 accumulation and probable inactivation 
due to cytoplasmic sequestration (Tweddle et al., 2003). Another stapled α−helical peptide has 
emerged, ATSP-7041 (Aileron therapeutics USA, clinical trial phase I). ATSP-7041 is a potent 
dual inhibitor of MDM2 and MDMX which consequently activates p53 pathway in tumors 
(Chang et al., 2013a). Another p53 inducing small molecule, which inhibits p53-MDM2 
interaction, Nutlin-3 (Roche, nutlin-3 like molecule in clinical trial phase III) (Vassilev et al., 
2004), was used in this study. 
 
Myc also has a pivotal role in cancer, and in the maintenance of the cancer cells. It augments 
the genesis of many human cancers as it is a pleiotropic transcription factor that is existent at 
the crossroads of multiple pathways that is key of the cells’ fate. It can solely drive cancer 
progression and tumor growth (Castell, Yan, Fawkner, Zhang, et al., 2018). 
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Therefore, targeting activation of p53 and/or inhibition of MYC could be a potential therapy to 
induce immunogenicity in the fatal neuroblastoma. Previous research found a small molecule 
MYCMI-6 which blocks MYC-driven transcription and binds selectively as explained before, 
to the MYC bHLHZip domain (Castell, Yan, Fawkner, Zhang, et al., 2018). In this study, they 
originally experimented several MYC inhibitors, however, MYCMI-6 was the one of the 
specific and potent MYC:MAX inhibitor.  
 
It has been previously observed that one reason that contributes to the neuroblastoma metastatic 
trait is the amplification of N-Myc gene. When N-Myc is amplified, MHC class I is repressed, 
however, this action could be remodeled again following interferon induction (Bernards et al., 
1986b). p53 has demonstrated strong direct transcriptional influence on IFN-inducible genes as 
IRF9, IRF5, ISG15 and TLR3. This exhibits how p53 has a central lead in activation of antiviral 
innate immunity either through apoptosis or through encouraging type I IFN response (Rivas 
et al., 2010). Furthermore, a previous study showed that MYC can negatively impact STAT1 
(A primary transcription factor stimulated by interferons and has a central role connecting the 
Type I and Type II interferon responses). Thus, inhibition of MYC expression results directly 
or indirectly in stimulation of STAT1, this in turn activates and triggers Type I interferons 
(Schlee et al., 2007). Also, IRF7 which is a crucial governor of Type I IFN response was found 
to be depleted or greatly repressed by MYC. It was shown that MYC is found at the IRF 
promoter region together with a nuclear receptor corepressor 2/histone deacetylase 3. When 
MYC was inhibited, IRF7 expression was greatly induced (T. W. Kim et al., 2016).  From these 
findings, we wanted to test the effect of the combined treatment (N-Myc inhibition and p53 
activation). It was also found that ERVs can function as tumor-associated antigens activating 
both T-cell and B-cell immune responses in tumors (Wang-Johanning et al., 2008). 
Nevertheless, whether N-myc inhibition and/or p53 activation treatment would have the same 
effect in neuroblastoma cell lines or the possible effect on the tumor immunogenicity has not 
been covered yet. In our study this is what we aimed for, after those collective findings, we 
were intrigued to investigate how and if the induction of immunogenicity in the fatal 
neuroblastoma could be possibly induced using co-treatment. 
 
Following combination treatment, we observed remarkable interferon signaling, and induced 
IFN- RNA levels. Consequently, activation in some of the antigen processing and presenting 
genes was noted in both cell lines using qPCR. And on protein level,  ISG-15 and pSTAT1 
were also induced. Our results suggest significant induction in comparison to single-treatment, 
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as well as p53-dependency in IMR-32 cells causing this noted induction (as demonstrated in 
the results section). 
 
Myc was found to suppress transcription by functional involvement with transcriptional 
activating genes. Myc through the interaction and linking with Dnmt3a and DNMTs activity in 
vivo, represses the p21Cip1 (implied in p53 mediated inhibition of cell proliferation) gene 
promoter (Brenner et al., 2005). This shows the intertwined role of Myc in encouraging cell 
proliferation and growth even further by interfering with p53. While, it was shown that when 
p53 is overexpressed, DNMT1 protein expression is repressed (L. Zhang et al., 2016). 
Correspondingly, our combination treatment in neuroblastoma by inhibiting Myc and activating 
p53 couple between these findings, possibly exhibiting stronger impact on the overall tumor 
immunogenicity.
Fig. 15: A proposed model depicting how p53-activator and Myc-
inhibitor regulates tumor responses to host immunity 
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7. Conclusion 
Ablating the DNA methyltransferase 1 (DNMT-1) pharmacologically (using combination of 
p53-activator, ATPS-7041 and N-Myc inhibitor, MYCMI-6) enhances tumor immunogenicity 
by stimulating endogenous retrovirus expression and Interferon signaling. 
Given the general role of p53-activator and Myc-inhibitor in regulating dsRNA and IFN 
responses, targeting both in combination may prove to be a universally applicable new strategy 
to overcome resistance. 
Further work is needed to explore the function of p53 and Myc in immune cells. Moreover, 
further experiments need to be carried out for absolute confirmation.  
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8. Future perspective 
Subsequent steps in our project could be performing of an enzyme-linked immunosorbent assay 
(ELISA) to further confirm IFN-β production. MHC class-I expression and the dsRNA stress 
could also both be further studied using Fluorescence-activating cell sorting analysis (FACS). 
The gold standard anti-dsRNA monoclonal antibody J2 for detecting the dsRNA could be 
accomplished to conclude both FACS and qPCR results.  
 
Furthermore, knocking-out of p53 using CRISPR/Cpf1 system in SH-SY5Y cell line shall be 
carried out to prove p53 dependency, as confirmed in IMR-32 cell line.  
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